Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.

MLA

Sakagami, Mai, et al. “Clinical Features and Risk Factors for Interstitial Lung Disease Spreading in Low-Dose Irradiated Areas after Definitive Radiotherapy with or without Durvalumab Consolidation Therapy for Patients with Non-Small Cell Lung Cancer.” Radiation Oncology, vol. 18, no. 1, May 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13014-023-02276-7.

APA

Sakagami, M., Inokuchi, H., Mukumoto, N., Itoyama, H., Hamaura, N., Yamagishi, M., Mukumoto, N., Matsuda, S., Kabata, D., & Shibuya, K. (2023). Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer. Radiation Oncology, 18(1), 1–10. https://doi.org/10.1186/s13014-023-02276-7

Chicago

Sakagami, Mai, Haruo Inokuchi, Nobutaka Mukumoto, Hiroshige Itoyama, Nobunari Hamaura, Mutsumi Yamagishi, Naoki Mukumoto, Shogo Matsuda, Daijiro Kabata, and Keiko Shibuya. 2023. “Clinical Features and Risk Factors for Interstitial Lung Disease Spreading in Low-Dose Irradiated Areas after Definitive Radiotherapy with or without Durvalumab Consolidation Therapy for Patients with Non-Small Cell Lung Cancer.” Radiation Oncology 18 (1): 1–10. doi:10.1186/s13014-023-02276-7.